Juvena Therapeutics

Executive Summary

Juvena Therapeutics is a private biotech company headquartered in Redwood City, California, focused on unlocking the therapeutic potential of secreted proteins to restore tissue health and combat degenerative diseases. Founded in 2018, the company leverages a proprietary platform that maps natural secreted proteins and engineers them into biologic therapies, aiming to repair dysregulated protein signaling and intercellular communication. By targeting the root causes of tissue degeneration, Juvena's approach has broad applicability across age-related and chronic conditions, positioning it as a promising player in the regenerative medicine space. The company is advancing its lead pipeline candidates toward the clinic, with a strong emphasis on preclinical validation and platform expansion. Juvena has attracted attention for its innovative strategy and potential to address high unmet medical needs. While still in early stages, the company's progress in identifying and developing first-in-class biologics suggests significant upside if clinical translation succeeds. Key upcoming catalysts include the initiation of first-in-human studies, additional financing rounds to support R&D, and data readouts from preclinical models.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical trial initiation for lead candidate40% success
• Q2 2026Series B or C financing round70% success
• Q3 2026Preclinical data presentation at major conference80% success